trial

Recovery With Exogenous Ketones and Antipsychotics

NCTId NCT07122531
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 15 (estimated)
Sponsored by Université de Sherbrooke
Primary completion 2027-04-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
15 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-08-26
Primary completion
2027-04-15
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Medium chain triglyceride oil

Sponsors

Université de SherbrookeLead Sponsor

Investigators

1
Kevin Zemmour, MDPrincipal Investigator

Sites

1 total
Sherbrooke, Canada

Facts & assertions

4 sourced
Enrollment
15
Phase
NA
Primary Completion Date
2027-04-15
Status
RECRUITING
relationships
The graph out of here
drug
Medium chain triglyceride oil
drug
lead_sponsor
Université de Sherbrooke
company
indication
Ketosis
indication
Schizophrenia
indication
First Episode Psychosis
indication
investigator
Kevin Zemmour, MD
person